By Small Pharma Analyst:Vertex (VRTX) is a 25-year old biopharma company that has had more than its share of ups and downs over the years - and yet another company-defining event is just around the corner.
Robert Weinstein submits:
The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War.
Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.
Vertex Pharmaceuticals Incorporated (VRTX) is scheduled to announce earnings for the second quarter of its 2014 fiscal year (2QFY14) on July 29, after the market closes. Analysts expect a 14.7% year-over-year decrease in earnings. The revenue for the quarter is expected to decrease 58.3% year-over-year to $131.9 million.
Vertex Pharmaceuticals Incorporated (VRTX) stock rose about 3.5% during yesterday's trading session, and is up another 1.29% in after-hours, on news that a US Food and Drug Administration's (FDA) advisory panel voted 13-2 in favor of expanding the company’s cystic fibrosis drug Kalydeco label to include a wider range of patients affected by the rare lung disease.
Bert Wilkison submits:On 04/07/11, Vertex Pharmaceuticals (VRTX) made headlines when it announced that one of its long time collaborators, Cystic Fibrosis Foundation Therapeutics, agreed to provide up to $75M over the next five years to support research and development for some of Vertex's early stag
By Brian L. Wilson:Anyone who was watching Vertex Pharmaceuticals (VRTX) yesterday (October 11th, 2012) probably noticed the huge ~5% drop that was followed with an immediate reversal and subsequent decline. Vertex is normally a very calm and slow-moving stock, so any VRTX investors caught off guard may have added to the volatility with reactionary decisions.